Alice Goodman

Treatment initiation for hormone-sensitive metastatic prostate cancer should include the addition of docetaxel to androgen deprivation therapy (ADT) as standard of care.

A new study suggests that the presence of persistent genetic mutations, 30 days after induction chemotherapy, predicted relapse and survival in patients with acute myeloid leukemia (AML), as well as intermediate-risk patients.

It is well known that having multiple moles (ie, >50) is a risk factor for developing melanoma. A new study shows, however, that melanoma can also develop in people with fewer than 50 moles, and when it does, it typically has a more aggressive course.

Patients with bladder cancer who undergo robot-assisted radical cystectomy (RARC) appear to have acceptable 5-year survival, according to the largest multi-institutional series to date to collect data on RARC outcomes in this population.

Two different types of liquid biopsies—plasma and urine—can detect the number of copies of the KRAS mutation in circulating DNA in patients with colorectal cancer who have resectable liver metastases with near 100% concordance with tissue biopsies, according to a pilot study presented at the 2015 Annual Meeting of the American Association for Cancer Research (AACR).

A prospective study of retrospectively analyzed blood samples of patients with nonresectable pancreatic cancer found that plasma KRAS mutational burden correlates with overall survival (OS).